2,765 results on '"de Boer, Rudolf A."'
Search Results
102. The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise
103. Abstract 12547: Obesity as Risk Factor for Malignant Ventricular Arrhythmias in Phospholamban Cardiomyopathy
104. Abstract 12434: ECG-Only Deep Learning Algorithm Predicts Risk of Arrhythmia in Phospholamban Cardiomyopathy
105. Abstract 11933: Cardiac and Fibrosis-Related Biomarker Levels Do Not Predict Disease Development in Presymptomatic Phospholamban Cardiomyopathy
106. Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease: JACC State-of-the-Art Review
107. Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
108. Cardiovascular Risk Factors Are Associated With Future Cancer
109. Discovery of novel heart rate-associated loci using the Exome Chip
110. Variability of biomarkers in patients with chronic heart failure and healthy controls
111. Preoperative cardiac screening using NT-proBNP in obese patients 50 years and older undergoing bariatric surgery: a study of 310 consecutive patients
112. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF:The DELIVER Trial
113. RELEASE-HF study:a protocol for an observational, registry-based study on the effectiveness of telemedicine in heart failure in the Netherlands
114. Guideline implementation, drug sequencing, and quality of care in heart failure:design and rationale of TITRATE-HF
115. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD):a multicentre, pragmatic, cluster-randomised, controlled trial
116. Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction:Rationale and design of the HF-REVERT trial
117. Effects of Dapagliflozin in Patients in Asia:A Post Hoc Subgroup Analysis From the DELIVER Trial
118. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin:A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER
119. Mediators of the association between albuminuria and incident cancer:the PREVEND study
120. The different risk of new-onset, chronic, worsening, and advanced heart failure:A systematic review and meta-regression analysis
121. Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial
122. Penetrance and Prognosis of MYH7 Variant-Associated Cardiomyopathies: Results From a Dutch Multicenter Cohort Study
123. Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia:a landmark study
124. Cost-effectiveness of remote haemodynamic monitoring by an implantable pulmonary artery pressure monitoring sensor (CardioMEMS-HF system) in chronic heart failure in the Netherlands
125. An increase in albuminuria is associated with a higher incidence of malignancies
126. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
127. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect
128. Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.
129. Proactive screening for symptoms: A simple method to improve early detection of unrecognized cardiovascular disease in primary care. Results from the Lifelines Cohort Study
130. Current understanding of fibrosis in genetic cardiomyopathies
131. Effect of Galectin 3 on Aldosterone-Associated Risk of Cardiovascular Mortality in Patients Undergoing Coronary Angiography
132. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial
133. Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
134. The year in cardiovascular medicine 2023: the top 10 papers in heart failure and cardiomyopathies
135. An increase in albuminuria is associated with a higher incidence of malignancies
136. Advancing the fight against fibrosis in patients with heart failure: The contribution of sodium–glucose cotransporter 2 inhibition
137. RELEASE-HF study: a protocol for an observational, registry-based study on the effectiveness of telemedicine in heart failure in the Netherlands
138. Mediators of the association between albuminuria and incident cancer: the PREVEND study
139. Guideline implementation, drug sequencing, and quality of care in heart failure: design and rationale of TITRATE‐HF
140. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials
141. Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies
142. DWORF Extends Life Span in a PLN-R14del Cardiomyopathy Mouse Model by Reducing Abnormal Sarcoplasmic Reticulum Clusters
143. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
144. The year in cardiovascular medicine 2022: the top 10 papers in heart failure and cardiomyopathies
145. The emerging plasma biomarker Dickkopf-3 (DKK3) and its association with renal and cardiovascular disease in the general population
146. A new classification of cardio-oncology syndromes
147. Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
148. Incidence of atrial fibrillation, ischaemic heart disease and heart failure in patients with diabetes
149. Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)-Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
150. Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.